Consumer IPOs from Snap to Uber have been disappointing and serve as a reminder that private investors are making all the money.Technologyread more
The company's comments Friday come after the White House said U.S.Trade Representative Robert Lighthizer will "address the threatened impairment" of national security from...Autosread more
China's currency has been an important barometer for progress in U.S.-Chinese trade talks, and right now it's signaling things aren't going well.Market Insiderread more
Apple CEO Tim Cook was the commencement speaker at Tulane University Saturday. In his speech, the tech executive focused on the importance of addressing climate change and...Power Playersread more
Amazon's large and flashy investments stand out from those of its tech peers over the past year.Technologyread more
Some analysts see streaming services like Netflix becoming hindered by one of the things that made them so popular in the first place — binge watching.Entertainmentread more
There is a shortfall of cybersecurity workers that could reach as high as 3.5 million unfilled roles by 2021. A start-up called Synack provides crowdsourced security, and...CNBC Disruptor 50read more
Yardeni Research's Edward Yardeni recommends investing in U.S. companies with exposure to China.Trading Nationread more
CNBC and SurveyMonkey's latest small business optimism index echoes that sentiment, finding 52 percent of small businesses say it's harder to find workers today than it was a...US Economyread more
CNBC combed through Wall Street research over the last week to see which stocks analysts say have the best risk-reward.Marketsread more
Western Union is not panicking, but the delivery of money around the world is being upended, says CEO of upstart TransferWise. It broke into the $689 billion remittances...CNBC Disruptor 50read more
Acquisitions and breakthroughs abound in a sector brimming with options ripe for growth. Traders on CNBC's "Fast Money" outlined their strongest plays in the ever-volatile space.
"This merger party doesn't seem to be ready to die down any time soon," said trader Karen Finerman.
After enjoying a stellar 2014, funds exposed to biotech remain the "easy way out," Finerman said. The SPDR S&P Biotech ETF and iShares Nasdaq Biotechnology ETF, both up more than 25 percent in the last year, moved higher again on Monday.
The First Trust NYSE Arca Biotechnology Index Fund—which holds smaller companies in the sector—hit a 52-week high on Monday.
With stellar fund performance, individual stocks are also poised to do well, traders said. Biotech may have more room to run after some wild upward runs in 2014.
Gilead, for example, hit a snag at the end of last year amid concerns over drug prices. The stock has still gained more than 30 percent in the last year and has settled over $100 per share.
"It's right back where it should be, probably headed higher," said trader Guy Adami.
Adami will watch Agios, which is "still pretty interesting," and Celgene, which is "a name forever."